Market Survey on Andersen Tawil Syndrome Treatment Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Andersen Tawil Syndrome Treatment Market including Carbonic Anhydrate Inhibitors, Acetazolamide, Dichloropenamide, Antiarrhythmic Drugs, Amiodarone, Flecainide, Beta-Blockers, and Atenolol Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
Andersen Tawil Syndrome Treatment Market Snapshot (2023 to 2033)
The global Andersen Tawil syndrome treatment market is expected to surpass an impressive valuation of US$ 1.9 Billion in 2023 and is projected to reach US$ 4.2 Billion by 2033, with a CAGR of 8.26%
An increase in the prevalence of Andersen-tawil syndrome is expected to drive the growth of the market. The increasing focus of the government to prioritize drugs for the treatment of rare diseases may also propel the growth of the Andersen-Tawil syndrome market during the forecast period. The increasing participation of organizations to support the treatment and to create awareness is also expected to drive the growth of the market. The rising Research and Development investments by the key players in the Andersen-Tawil Syndrome Market are also expected to boost the growth of the market.
However, the lack of large clinical studies may restrict the growth of the Andersen-Tawil syndrome market. The shortage of healthcare expected in the Middle East & Africa and Latin America may restrain the growth of the Andersen-Tawil Syndrome market in this region. The drug acetazolamide is likely to help with muscle weakness attacks, as well as dichlorphenamide (brand name KEVEYIS, the only FDA-approved periodic paralysis treatment).
Report Attribute
Details
Expected Market Value (2023)
US$ 1.9 Billion
Anticipated Forecast Value (2033)
US$ 4.2 Billion
Projected Growth Rate (2023 to 2033)
CAGR 8.26%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Andersen Tawil Syndrome Treatment Demand Analysis vs. Forecast 2023 to 2033
The market for Andersen Tawil Syndrome Treatment was worth US$ 1.4 Billion in 2018 while growing at a CAGR of 6.3%. The increasing focus of the government to prioritize drugs for the treatment of rare diseases and growing participation from various organizations to treat this disease has been pushing healthcare industries and manufacturers to come up with next-generation drugs like ‘Acetazolamide’ for treatment of Andersen Tawil syndrome.
These developments have provided a boost for this market. Considering these factors, demand for this market is projected to grow at a CAGR of 8.26%, reaching a valuation of US$ 4.2 Billion.
Which are Some Prominent Drivers of the Andersen Tawil Syndrome Treatment Market?
Mounting Research and development activities will propel the market expansion
Rising government funding for diagnostic procedures is likely to offer attractive opportunities for the Andersen-Tawil Syndrome diagnostic and treatment market which will lead to growth in product demand. The rising prevalence of disease, growing government initiatives, advancement in treatment options, genetic counseling, and increasing awareness of rare diseases are the factors that will expand the global Andersen disease treatment market.
Expanding Research and Development activities and the growing focus of major pharmaceutical companies toward novel treatment therapies will provide beneficial opportunities for the global Andersen disease treatment market in the forecast period of 2023 to 2033.
Moreover, the adoption of some of the more prominent diagnostic and treatment options including potassium supplements, molecular genetic testing, voluntary muscle contraction exercises, Holter monitoring, and electrocardiograms are anticipated to fuel market expansion.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Projected to be Faced by the Market?
The high cost of treatment, slow growth in the adoption of novel drugs, and lack of awareness are the factors that will hamper the Andersen Tawil Syndrome Treatment market. Moreover, the availability of generic drugs is also expected to restrict market expansion.
Region-Wise Insights
North America dominates the market for Andersen Tawil Syndrome Treatment
North America dominates the Andersen disease treatment market due to the presence of major key players, advancement in treatment options, well-developed healthcare sector, rising prevalence of disease, and growing awareness towards health in this region.
Andersen Tawil Treatment market will witness great advancement in this region during the assessed time span. The improvement would be possible because of marketing examination instruments and because of existing players that are positively gotten comfortable with the market since the beginning.
Also, organization associations, associations, outcast chiefs, etc are channelizing their undertakings to make customer-driven things which will moreover add to the advancement in this locale. Increasing revenue, extended compensation, pattern setting advancement, and contraption, close by the tasks for spreading the thoughtfulness regarding the need will presumably make the Andersen Tawil therapeutics market grow tremendously.
South Asia to emerge as an Opportunistic Hub in Forthcoming Years
Andersen disease treatment market in South Asia is expected to grow during the forecast period due to the increasing research and development activities, increasing investment in the healthcare sector, emerging markets, and mounting government support.
South Asia is anticipated to experience the fastest growth in the Andersen-Tawil Syndrome market owing to improving healthcare infrastructure along with a rise in the number of cases suffering from the disease. In addition, increasing awareness may also help to fuel the growth of the Andersen-Tawil Syndrome market at a faster rate in this region. The developing private healthcare in countries like India is also expected to contribute to the growth of the Andersen-Tawil Syndrome market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category wise Insights
Type 1 Andersen Tawil Syndrome Treatment dominating the segment growth
Type 1 Andersen Tawil Syndrome Treatment dominates the segment by disease type with a market share of around 59% and a segment CAGR of 5.4%. The growth is attributed as highest in this segment because type 1 disease is caused by a known KCNJ2 gene mutation making it easier to identify and commence the treatment of the disease. North America is anticipated to dominate the industry for Type 1 disease treatment followed by Europe during the forecast period.
The hospital segment is expected to dominate the market by distribution channel
Hospital pharmacies accounted for 55% market share in 2022, followed by Online pharmacies. This segment is expected to retain its dominance by end of 2033 owing to well-developed health infrastructure, rising government initiatives, and growing investments in innovating drugs for the treatment of Andersen Tawil Syndrome Treatment is likely to augment this segment growth and fuel the industry’s demand.
Start-ups in Andersen Tawil Syndrome Treatment Market
Founded in 2013,Lambda Health System is a developer of game-based robotic therapy for rehabilitation. The company is involved in the development of health systems that develops robotic equipment for assisted rehabilitation for people recovering from neurological injuries. It offers Lambda Robot, which is a rehabilitation device with 2 robotic arms. The arms have fixtures to hold the patient's legs and can adapt to a particular person. The company intends to make robotic rehabilitation a common theme in the treatment option for neural paraplegia. It has raised a total funding of US$ 31.2 K from ‘Venture Kick’.
Founded in 2008, Good Start Genetics is a molecular genetic information company based in Boston, US that offers carrier screening for inherited genetic diseases. The company provides genetic carrier screening tests for known and novel mutations that cause inherited genetic disorders. The company is using next-generation sequencing (NGS) and other proven genetic screening technologies for their genetic tests. Good Start Genetics provides carrier screening for all disorders recommended by the American Congress of Obstetricians and Gynecologists & the American College of Medical Genetics. It has two products: GeneVu for carrier testing and EmbryVu for embryo screening. Customers can order GeneVu through Amazon as well. It has raised funding of USD 32 million from CRG, Orbimed, Safeguard Scientifics, and 1 Other Investor.
Market Competition
Key players in the Andersen Tawil Syndrome Treatment Market are: Teva Pharmaceuticals Ltd, Zydus Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd., Advanz Pharmaceuticals, Novartis AG, Mylan N.V, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Viatris Inc, Pfizer Inc
Some recent developments in this market are:
In April 2021, Teva Pharmaceuticals was acquired by Karo Pharma Aktiebolag with the aim of gaining the European OTC brand portfolios and drug research including rare disease solutions. Also, Sun Pharmaceutical Industries Ltd. announced the acquisition of a 66% ownership interest in Trikaal Mediinfotech, and AWACS, through its subsidiary ABCD Technologies LLP.
In December 2016, Strongbridge Biopharma plc acquired U.S. commercialization rights for Keveyis from Taro Pharmaceutical Industries Ltd (a subsidiary of Sun Pharmaceutical Industries Ltd) for the treatment of periodic paralysis. Under the terms of the agreement, Taro Pharmaceutical Industries Ltd is to receive an upfront payment of US$ 8.5 Million and is also eligible to receive additional future payments upon the achievement of certain sales unit milestones. The acquisition of USA rights expands the company’s rare disease portfolio to include neuromuscular diseases.
In August 2015, Taro Pharmaceutical Industries Ltd received approval from the FDA for Keveyis (dichlorphenamide), an oral carbonic anhydrase inhibitor for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic, periodic paralysis, and related variants. The FDA approval of Keveyis is the most awaited, new, effective treatment option for many years for patients suffering from periodic paralysis.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 1.9 Billion
Market Value in 2033
US$ 4.2 Billion
Growth Rate
CAGR of 8.26 % from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Disease Type
Drug Type
Distribution Channel
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Teva Pharmaceuticals Ltd
Zydus Pharmaceuticals, Inc.
Sun Pharmaceuticals Industries Ltd.
Advanz Pharmaceuticals
Novartis AG
Mylan N.V
Aurobindo Pharma
Dr. Reddy’s Laboratories Ltd.
Viatris Inc.
Pfizer Inc.
Customization
Available Upon Request
Key Segments Profiled in the Andersen Tawil Syndrome Treatment Market Industry survey
Disease Type:
Type 1
Type 2
Drug Class:
Carbonic Anhydrate Inhibitors
Acetazolamide
Dichloropenamide
Antiarrhythmic Drugs
Amiodarone
Flecainide
Beta-Blockers
Atenolol
Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Frequently Asked Questions
What is the Forecasted Growth Rate for the Global Anderson Tawil Syndrome Treatment Market?
The global market is forecasted to develop at an impressive 8.26% CAGR until 2033.
Which is the Net Worth of the Global Market for Anderson Tawil Syndrome Treatment Services?
The total demand in 2023 is estimated to generate a revenue of around US$ 1.9 billion.
What is the Growth Trend in South Asia in Adoption of Anderson Tawil Syndrome Treatment Services?
Rising government spending on healthcare infrastructure is driving the regional market at a faster rate.
Which End User Segment Creates a Higher Demand for Anderson Tawil Syndrome Treatment?
Hospital Pharmacies segment generated almost 55% of the total revenue in 2022.
Which Type of Anderson Tawil Syndrome Treatment is the Largest Segment in the Global Market?
Type 1 Anderson Tawil Syndrome created nearly 59% of the global demand in 2022.
Table of Content
1. Executive Summary | Andersen Tawil Syndrome Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033
5.3.1. Type 1
5.3.2. Type 2
5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug-class
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug class, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug class, 2023 to 2033
6.3.1. Carbonic Anhydrate Inhibitors
6.3.2. Acetazolamide
6.3.3. Dichlorpenamide
6.3.4. Antiarrhythmic Drugs
6.3.5. Amiodarone
6.3.6. Flecainide
6.3.7. Beta-Blockers
6.3.8. Atenolol
6.4. Y-o-Y Growth Trend Analysis By Drug class, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Drug class, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East and Africa(MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Disease Type
9.2.3. By Drug-class
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease Type
9.3.3. By Drug-class
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Disease Type
10.2.3. By Drug-class
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease Type
10.3.3. By Drug-class
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Disease Type
11.2.3. By Drug-class
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease Type
11.3.3. By Drug-class
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Disease Type
12.2.3. By Drug-class
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease Type
12.3.3. By Drug-class
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Disease Type
13.2.3. By Drug-class
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Disease Type
13.3.3. By Drug-class
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Disease Type
14.2.3. By Drug-class
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Disease Type
14.3.3. By Drug-class
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of Middle East and Africa(MEA)
15.2.2. By Disease Type
15.2.3. By Drug-class
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Disease Type
15.3.3. By Drug-class
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Disease Type
16.1.2.2. By Drug-class
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Disease Type
16.2.2.2. By Drug-class
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Disease Type
16.3.2.2. By Drug-class
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Disease Type
16.4.2.2. By Drug-class
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Disease Type
16.5.2.2. By Drug-class
16.5.2.3. By Distribution Channel
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Disease Type
16.6.2.2. By Drug-class
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Disease Type
16.7.2.2. By Drug-class
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Disease Type
16.8.2.2. By Drug-class
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Disease Type
16.9.2.2. By Drug-class
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Disease Type
16.10.2.2. By Drug-class
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Disease Type
16.11.2.2. By Drug-class
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Disease Type
16.12.2.2. By Drug-class
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Disease Type
16.13.2.2. By Drug-class
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Disease Type
16.14.2.2. By Drug-class
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Disease Type
16.15.2.2. By Drug-class
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Disease Type
16.16.2.2. By Drug-class
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Disease Type
16.17.2.2. By Drug-class
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Disease Type
16.18.2.2. By Drug-class
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Disease Type
16.19.2.2. By Drug-class
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Disease Type
16.20.2.2. By Drug-class
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Disease Type
16.21.2.2. By Drug-class
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Disease Type
17.3.3. By Drug-class
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Teva Pharmaceuticals Ltd.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Zydus Pharmaceuticals, Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Sun Pharmaceuticals Industries Ltd.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Advanz Pharmaceuticals
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Novartis AG
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Mylan N.V.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Aurobindo Pharma
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Dr. Reddy’s Laboratories Ltd.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Viatris Inc.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Pfizer Inc.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Drug class, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Drug class, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Drug class, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Drug class, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Drug class, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Drug class, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Drug class, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Drug class, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Drug class, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Drug class, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Drug class, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Drug class, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 17: Global Market Attractiveness by Disease Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Drug class, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Drug-class, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Drug class, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Drug class, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Drug class, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 37: North America Market Attractiveness by Disease Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Drug class, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Drug class, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Drug class, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Drug class, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Drug class, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Disease Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Drug class, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Drug class, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Drug class, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Drug class, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Drug-class, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 77: Europe Market Attractiveness by Disease Type, 2023 to 2033
Figure 78: Europe Market Attractiveness by Drug class, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Drug class, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Drug class, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Drug class, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Drug class, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 97: South Asia Market Attractiveness by Disease Type, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Drug class, 2023 to 2033
Figure 99: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Drug class, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Drug class, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Drug class, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Drug class, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 117: East Asia Market Attractiveness by Disease Type, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Drug-class, 2023 to 2033
Figure 119: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Drug class, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Drug-class, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Drug-class, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Drug-class, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 137: Oceania Market Attractiveness by Disease Type, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Drug-class, 2023 to 2033
Figure 139: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Drug-class, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Drug-class, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Drug class, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Drug-class, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 157: MEA Market Attractiveness by Disease Type, 2023 to 2033
Figure 158: MEA Market Attractiveness by Drug class, 2023 to 2033
Figure 159: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
